Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation

Mitralign, Inc.50 enrolled

Overview

The purpose of this study is to test the safety and device performance of the Mitralign system ("MPAS") to treat functional mitral valve regurgitation.

The ALIGN study is a single arm, prospective study. The objective of the study is to investigate the safety and performance of a catheter-based plication device intended to reduce the circumference of the dilated mitral valve. The study will enroll up to 50 subjects from up to 5 sites (Paraguay, Columbia, Dominican Republic, Brazil, and India) who will be followed for 36 months post index procedure. Enrollment is defined at the time the study device is inserted into the body and patients will be followed at 30 days, and Months 6, 12, 24 and 36 post index procedure.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Mitral Valve Regurgitation

Interventions

percutaneous annuloplastyDEVICE

plication of the mitral valve annulus

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * NYHA II-IV * Structurally normal mitral valve * At least Grade 2 mitral regurgitation * Left ventricular ejection fraction not less than 20% and not greater than 45% * Left ventricular end diastolic diameter not less than 5.0 cm and not greater than 7.5 cm Exclusion Criteria: * Pregnant or lactating female * Mitral stenosis * Mod/severe aortic stenosis or regurgitation * Mod/severe tricuspid stenosis or regurgitation * Endocarditis * Previous mitral valve repair or MV replacement * Bioprosthetic or mechanical aortic valve * Known unstable angina or MI within 30 days prior to procedure * CVA within past 6 months * Known contraindications to blood transfusion, contrast dye, DAPT

Locations (8)

Clinica CardioVID

Medellín, Antioquia, Colombia

Antonio Dager, MD

Valle Del Cauca, Cali, Colombia

Bordeaux Heart University Hospital

Bordeaux-Pessac, France

Clinique Pasteur

Toulouse, France

Outcomes

Primary Outcomes

Major Adverse Events (MAE)

MAE defined as occurrence of any of the following: Mitral valve-related surgery/intervention, myocardial infarction, cardiac tamponade, stroke, device and/or procedure-related death

Time frame: within 30 days post procedure

Secondary Outcomes

Echocardiographic Outcomes

Freedom from an increase in ventricular diameter

Time frame: at 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.